Picture Berlin Partner Hotspot for Startups 650x80px
Organisation › Details

Rodin Therapeutics Inc.

Rodin Therapeutics is discovering and developing first in class therapeutics for neurological disorders, applying unique insights into the role of epigenetics and novel chemical strategies to target specific HDAC complexes. Rodin’s unique translational strategy, along with a targeted approach to synaptic resilience, has potential for multiple phenotypically diverse diseases – such as Parkinson’s disease, Alzheimer’s disease, Frontotemporal dementia, post-traumatic stress disorder and traumatic brain injury - which all share the common root cause of impaired neuronal and synaptic function. *


Period Start 2013-03-01 established
  Group Alkermes (Group)
Products Industry CNS drug
  Industry 2 structure-based drug design
Persons Person Rosenberg, Adam (Rodin Therapeutics 201601 CEO)
  Person 2 Booth, Bruce (Atlas Venture 201306 Partner)
Region Region Cambridge, MA
  Country United States (USA)
  Street 300 Technology Square
8th Floor, Life Sciences Suites
  City 02139 Cambridge, MA
    Address record changed: 2020-12-02
Basic data Employees n. a.
    * Document for �About Section�: Rodin Therapeutics Inc.. (9/18/17). "Press Release: Rodin Therapeutics Advances Synaptic Resilience Strategy with $27 Million in Financing and Expands Board of Directors". Cambridge, MA.
Record changed: 2020-03-03


Picture [iito] Plain Stupid Simple 650x80px

More documents for Alkermes (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture [iito] Back into Ad 650x80px

» top